ZURA
Zura Bio Limited Class AstockNASDAQ
zura bio is a clinical-stage biotechnology company advancing zb-168 in alopecia areata and other inflammatory diseases. zb-168 is an anti il7rα inhibitor that has the potential to impact diseases driven by il7 and tslp biological pathways. zura bio aims to develop a portfolio of therapeutic indications for zb-168, and is focused on demonstrating its efficacy, safety, dosing convenience and mechanism of action, initially in alopecia areata. this will build on phase 1b data in type 1 diabetes demonstrating a favourable safety profile and strong biological rationale. zura bio is headquartered in london, uk with team members in the uk and usa.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.10 | 2026-09-28 | +0.12% | -1.780 |
| 1M | 6.23 | 2026-09-04 | -34.11% | 1.299 |
| 3M | 5.36 | 2026-07-06 | -23.41% | 1.321 |
| 6M | 6.06 | 2026-04-06 | -32.26% | 1.170 |
| 1Y | 4.17 | 2025-10-06 | -1.56% | 1.612 |
| 2Y | 4.38 | 2024-10-04 | -6.28% | — |
| 5Y | 30.00 | 2023-03-22 | -86.32% | 1.448 |
Zura Bio Limited Class A (NASDAQ:ZURA) stock price today is $4.11, and today's volume is 2,954,783. ZURA is down 0.845% today. The 30 day average volume is 2.02M. ZURA market cap is $393.38M with 95.83M shares outstanding.